Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of APP13007 for inflammation and pain after cataract surgery
ChiCTR2300076680Phase 3Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2023
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GPN00833 in Postoperative ocular inflammation, post-operative ocular pain and cataract (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Proportion of subjects with anterior chamber cell count = 0 after cataract surgery and Proportion of subjects with ocular pain grade = 0 after cataract surgery. Started Apr 2023; status: recruiting.
02
Drugs
GPN00833
03
Conditions
Postoperative ocular inflammationpost-operative ocular paincataract
Beyond the preview
Go deeper on ChiCTR2300076680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076680.